Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop new drugs, including its slate of experimental weight loss and diabetes medications.

A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the drug continuously for about a year and 4 months and then stopping. It found that about two-thirds regained the weight they lost. A similarly designed study had comparable results for tirzepatide (Zepbound).